The GW Vaccine Research Unit

In observance of HIV Vaccine Awareness Day on Saturday, May 18, NIAID expresses its gratitude to the dedicated global community of scientists, advocates, study participants, study staff, and funders working toward a safe, effective, durable, and accessible HIV vaccine.

NIAID Marks HIV Vaccine Awareness Day 2024 On the 27th observance of HIV Vaccine Awareness Day (Saturday, May 18), we express our gratitude to the dedicated global community of scientists, advocates, study participants, study staff, and funders working toward a safe, effective, durable, and accessible HIV vaccine.

The GW VRU Director, Dr. David Diemert, weighs in on two candidate vaccine viruses for H5N1 bird flu that could be used to make vaccines in an outbreak.

Bird Flu: 100 Million Doses of Vaccine Could Be Shipped Within Months There is no sign that the H5N1 bird flu circulating in dairy cow herds is developing the ability to spread easily to people. But federal health officials are planning for the rollout of a bird flu vaccine as a precaution.

is recruiting volunteers ages 50 years and older and in good health for a combination COVID-19 and flu vaccine study. Visit https://redcap.link/combo_vax to volunteer if you have not received a COVID-19 vaccine or a flu vaccine in the past 6 months.

Are you willing to participate in current or future clinical trials?

https://redcap.link/gwvru_registry

Volunteers needed for a nasal microbiome study! https://redcap.link/nasalmb_laiv

Dr. Elissa Malkin attended the American Society of Tropical Medicine and Hygiene (ASTMH) Annual Meeting in Chicago where she presented data on a Lassa fever vaccine Phase I clinical trial for which she served as site P.I.

Recruiting for a nasal microbiome study! The bacteria that live inside your nose - your nasal microbiome - may affect your immune responses to the nasal flu vaccine! We are recruiting participants for a study that seeks to understand how your nasal microbiome affects the immune responses you develop in your nose and blood after we administer the licensed nasal flu vaccine ( ).

Interested? Please visit https://redcap.link/nasalmb_laiv to sign up and see if you may be eligible! Compensation provided.

Email us: [email protected]

Screening

mRNA Vaccines Moonshot | GW Research Magazine | The George Washington University mRNA vaccines changed the course of the COVID-19 pandemic. Now GW researchers are developing these vaccines to treat and prevent diseases from cancer and HIV to malaria and shingles.

Our own, Dr. David Diemert's research on COVAIL has just been published with Springer Nature in Nature Medicine. Read and share here:

Comparison of bivalent and monovalent SARS-CoV-2 variant vaccines: the phase 2 randomized open-label COVAIL trial - Nature Medicine Analysis of antibody responses to COVID-19 vaccines encoding variant-specific spike, with or without ancestral spike, suggests no loss of neutralization of the ancestral virus with variant-only vaccines, which may simplify future vaccine updates.

What to Know About the New R.S.V. Immunizations New vaccines for older adults and an antibody therapy for infants provide options for preventing severe infection.

is recruiting volunteers aged 50-69 and in good health for a shingles vaccine study. Visit https://redcap.link/gwshingles to volunteer if you have never had shingles or been vaccinated for shingles.

Read this article that includes our own Dr. David Diemert. The purpose of this article is to discuss the ongoing research regarding COVID-19!

Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study In a parallel-group, international, phase 3 study (ClinicalTrials.gov NCT04762680), we evaluated prototype (D614) and Beta (B.1.351) variant recombina…

George Washington's Vaccine Research Unit is participating in the Project NextGen clinical study. Read this article on the journey to preparing the vaccines and treatments for the next outbreak.

www.nejm.org

GW Vaccine Research Unit is recruiting immunocompromised volunteers who are 60 years of age and older to participate in a new RSV vaccine clinical trial. Visit https://redcap.link/RSV-SSA to sign up!

Pfizer RSV C3671023 Volunteer Interest Survey Please complete the survey below to express your interest in participating in the Pfizer RSV vaccine clinical trial at GW.

Vaccines have a tremendous impact on public health, and their importance has been emphasized by the COVID-19 pandemic. Check out this article to read about the current state of research and vaccine development.

The R&D landscape for infectious disease vaccines Discover the world’s best science and medicine | Nature.com

Sign Up Now: GWU is recruiting Teen Volunteers for an Mpox Vaccine Study Help advance science and get compensated! GWU needs teen vaccine participants. Area teens ages 12 to 17 are welcome to enroll in a clinical trial to study the mpox vaccine (formerly known as monkeypox) in adolescents. This NIH-led mpox trial is recruiting at the George Washington University Vacci

GW Vaccine Research Unit is recruiting immunocompromised volunteers who are 18 years of
age and older to participate in a new RSV vaccine clinical trial. Visit https://redcap.link/RSV-SSA to volunteer!

Pfizer RSV C3671023 Volunteer Interest Survey Please complete the survey below to express your interest in participating in the Pfizer RSV vaccine clinical trial at GW.

The GW Vaccine Research Unit is seeking volunteers to participate in a clinical trial that may help the mpox vaccine get FDA-approved in adolescents.

The GW Vaccine Research Unit is participating in a RSV vaccine study. Read more on what our own, Elissa Malkin, has to say about the RSV vaccine study by clicking the link below!

News Alert: RSV Vaccine Study for High-Risk Adults Launched | Media Relations | The George Washington University Pfizer has launched a Phase 3 study of its RSV vaccine candidate and GW researchers are studying the vaccine’s safety and effectiveness.

The GW Vaccine Research Unit is seeking volunteers to participate in a clinical trial that may help the mpox vaccine get FDA-approved in adolescents.

Mpox Vaccine Study Volunteer Interest Survey Please complete the survey below to express your interest in taking part in an mpox (previously known as monkeypox) clinical trial at The George Washington University (ClinicalTrials.gov Identifier: NCT05740982).

GW Vaccine Research Unit is recruiting immunocompromised volunteers who are 18 years of
age and older to participate in a new RSV vaccine clinical trial. Visit https://redcap.link/RSV-SSB to volunteer!

fb.me

We are currently participating in a RSV clinical trial here at GW. Are you interested into knowing more about RSV? Read this article that discusses the RSV vaccine. If you would like to volunteer, visit https://redcap.link/RSV-SSA sign up!
Click this link to view the article! https://www.washingtonpost.com/health/2023/05/03/rsv-vaccine-adults/

First vaccine targeting RSV wins FDA approval. More are coming. The shot will be used to protect against respiratory syncytial virus in older adults — a turning point in the six-decade-long vaccine effort.

Pfizer RSV C3671023 Volunteer Interest Survey Please complete the survey below to express your interest in participating in the Pfizer RSV vaccine clinical trial at GW.

The GW Vaccine Research Unit is recruiting volunteers who are at high risk for RSV disease. Volunteers should be between 18-59 years old. Check out the flyer below for more information and feel free to contact us with any other questions.
Interested in volunteering? Visit https://redcap.link/RSV-SSA to sign up!

fb.me

The GW Vaccine Research Unit is recruiting volunteers who are immunocompromised. Volunteers should be at least 18 years old. Check out the flyer below for more information and feel free to contact us with any other questions.
Interested in volunteering? Visit https://redcap.link/RSV-SSA to sign up!

The COVAIL trial is one of the clinical trials that we facilitate here at The GW Vaccine Research Unit. Click this link to read about results from the COVAIL trial!
https://academic.oup.com/cid/advance-article/doi/10.1093/cid/ciad209/7111740?utm_campaign=+56065410&utm_content=&utm_medium=email&utm_source=govdelivery&utm_term=

The GW Vaccine Research Unit is recruiting volunteers who are at high risk for RSV disease. Volunteers should be between 18-59 years old. Check out the flyer below for more information and feel free to contact us with any other questions.
Interested in volunteering? Visit https://redcap.link/RSV-SSA to sign up!

Here is our very own, Dr. David Diemert, in a short Q & A video answering questions about the Shingles vaccine trial. We are currently open for enrollment and are seeking for healthy participants who are between 50 and 69 years of age. Click the video or the link to view: https://www.cyranoapp.media/msg/?q=b568a3e5-dde0-11ed-a6ce-127eadaff8e0
Click this link to fill out the survey: https://redcap.link/gwshingles

Shingles Vaccine Q&A